Tris' allergy drug for children gets FDA OK

04/4/2013 | Drug Store News

The FDA approved Tris Pharma's Karbinal ER, or carbinoxamine maleate, for pediatric patients 2 years and older, to treat seasonal and perennial allergic rhinitis. The treatment is the first extended-release histamine receptor blocking agent for children's allergies, Tris said.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID